BioCentury
ARTICLE | Clinical News

Delamanid: Phase I data

July 30, 2012 7:00 AM UTC

An open-label Phase I trial in healthy volunteers showed that no clinically relevant changes in delamanid exposure occurred when the compound was co-administered with HIV drugs Viread tenofovir or Kaletra lopinavir/ritonavir. Additionally, Viread had no effect on delamanid exposure, while Kaletra produced a 20% increase in delamanid exposure which Otsuka said was possibly related to inhibition of cytochrome P450 3A4 (CYP3A4) by ritonavir. Data were presented at the International AIDS meeting in Washington. ...